Brief: Mateon Therapeutics terminates FOCUS study in ovarian cancer
26/09/2017 23:00
Sept 26 (Reuters) - Mateon Therapeutics Inc MATN.PK :
* Announces termination of focus study in ovarian cancer and
restructuring to prioritize OXi4503 for AML
* Company to reduce headcount, concentrate on OXi4503 for
Acute Myeloid Leukemia (AML)
* Remaining members of senior management team will take 50%
salary reductions, effective immediately
* Implementing various cost reduction measures, which
includes decrease in co's workforce of about 60% since beginning
of year
Source text for Eikon: ID:nGNXOENCJa
Further company coverage: MATN.PK
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas